Intermetatarsal Bursitis in Patients With Rheumatoid Arthritis
Reason given: The study was stopped due to health-related issues in the research group, that hindered inrolement of patients.
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Copenhagen University Hospital, Rigshospitalet
- Trial code
- NCT05698563
- Record updated
- 22 September 2025
- Original description
The aim of the study is to investigate the incidence and clinical implications of intermetatarsal bursitis (IMB) in patients with rheumatoid arthritis (RA).Read full original descriptionShow less
Clinical Implication of Intermetatarsal Bursitis in Patients With Rheumatoid Arthritis
The aim of the study is to investigate the incidence and clinical implications of intermetatarsal bursitis (IMB) in patients with rheumatoid arthritis (RA).
The hypothesis is that IMB is a cause of pain in patients with RA.
Inclusion: Age > 18 years; Forefoot pain and diagnosed with RA (patient group); Diagnosed with an axial arthritis (control group).
Exclusion: Persons with a history of significant trauma in the forefoot, e.g. any fracture or previous surgeries in the forefoot; Persons who have previously received intermetatarsal treatment (Morton's neuroma or IMB) in the same foot, e.g. injection within 6 months or operation at any time; Open wounds or ongoing infection in the forefoot at the time of examination; Persons with severely impaired renal function (GFR <30 ml/min); Age <18 years; Exclusion from MRI scan only:; Persons with contraindications to participate in MRI scan.